
Nyxoah SA (NYXH) Stock Forecast & Price Target
Nyxoah SA (NYXH) Analyst Ratings
Bulls say
Nyxoah is well positioned to capture a significant share of the growing market for obstructive sleep apnea treatment, with its innovative Genio system that has been validated in the European market and is now ramping up in the US. The company's recent financial results are indicative of strong commercial progress and its future revenue guidance reflects a potential for significant growth. While there are some potential risks, including competition from larger players and the need for additional capital, the overall positive outlook for the company is based on its solid product and successful launch in the US market.
Bears say
Nyxoah is showing positive growth indicators for its U.S. launch, with a significant increase in high-volume accounts and a developing patient funnel. However, there may still be confusion among physicians regarding HGNS coding, and the company's success will also depend on achieving breakeven at or below revenues of €150M. The company's plans for personnel and U.S. commercialization may help drive investor confidence.
This aggregate rating is based on analysts' research of Nyxoah SA and is not a guaranteed prediction by Public.com or investment advice.
Nyxoah SA (NYXH) Analyst Forecast & Price Prediction
Start investing in Nyxoah SA (NYXH)
Order type
Buy in
Order amount
Est. shares
0 shares